Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production ...

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central ...

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

Lending platform Pagaya Technologies on Monday announced an agreement to sell up... The owners of the distribution firm behind Irish fake tan brands such as Suzanne... Grant Thornton’s non-audit ...

Energy technology company SLB launched a new artificial intelligence tool on Monday to automate processes and workflows for ...

AI use cases now run the gamut. From early cancer detection and digital companionship to helping frustrated readers find ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

South Korean tech giant Samsung is making a major investment in artificial intelligence by building a factory powered by 50,000 Nvidia GPUs. This AI megafactory, as Samsung calls it, aims to ...

Accelerated returns have been common over the last few years, as powerful tech trends like artificial intelligence (AI) ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

M·A·C Cosmetics will debut in select U.S. Sephora locations and at Sephora at Kohl’s in early 2026, expanding its domestic retail footprint ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.